Jeffrey Alloway
Rheumatology · Greenville, NCNPI 1104829332
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,350 of the $45,598 with a category attached, or 81.9%. AbbVie accounts for 94.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $23,418 and has fallen 99.9% since, to $25 in 2024.
Across 360 payments — averaging $126.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Pfizer$568
- Amgen$565
- Novartis$387
- UCB, Inc.$189
- Lilly USA, LLC$181
- plus $856 from 15 others
Across 11 payments — averaging $1429.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$7K
- GSK$3K
- Pfizer$3K
- AbbVie$2K
- Gilead$500
- E.r. Squibb & Sons, L.L.C.$30
What the payments were for
- Speaking & faculty fees$37,35082%
- Travel & lodging$3,5448%
- Food & beverage$4,68910%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $42,853 |
| Pfizer | 90 | $568 |
| Amgen(2 entities) | 32 | $565 |
| Novartis | 25 | $387 |
| UCB, Inc. | 13 | $189 |
| Lilly USA, LLC | 16 | $181 |
| Johnson & Johnson(2 entities) | 13 | $163 |
| Regeneron Healthcare Solutions, Inc. | 8 | $103 |
| E.r. Squibb & Sons, L.L.C. | 7 | $96 |
| Bristol Myers Squibb | 5 | $74 |
| GSK | 4 | $63 |
| Genentech USA, Inc. | 4 | $57 |
| Mallinckrodt Enterprises LLC | 2 | $48 |
| Hikma Pharmaceuticals USA | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Boston Scientific | 2 | $38 |
| AstraZeneca | 2 | $36 |
| Boehringer Ingelheim | 2 | $28 |
| Medexus Pharma, Inc. | 2 | $27 |
| Fidia Pharma USA Inc. | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,598 in reported general payments places this provider in the 85th percentile of 210 rheumatology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MethotrexateMethotrexate Sodium | 14 | $253 |
| Duloxetine Hcl | 11 | $107 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Greenville
- Michael WattersonGreenville$12K
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
- Jill ZouzoulasCharlotte$377K
- Jill VargoAsheville$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.